Nama's AI scorecard currently rates Pediatrix Medical Group Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is MD's P/E ratio?

Pediatrix Medical Group trades at a trailing price-to-earnings ratio of 13.7.

When does MD report earnings?

Pediatrix Medical Group's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.63.

What is the MD price target?

The median analyst price target from 6 analysts is $29.00, with a range of $28.00 – $31.00.

Is MD Shariah compliant?

Nama's AAOIFI-style screen reads Pediatrix Medical Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Pediatrix Medical Group (MD)

Healthcare · Medical Care Facilities · NYSE

Pediatrix Medical Group (MD) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $2.44B, a trailing price-to-earnings ratio of 13.7 and a free-cash-flow yield of 9.5%. Over the most recent reported fiscal year, revenue declined 4.9% and free cash flow per share grew 33.8%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.5/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +18.4% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-7.3%

How far the last close sits under the highest price of the past five years.

Market cap	$2.44B
Trailing P/E	13.7
Price / book	2.9
Price / sales	1.2
FCF yield	9.5%
Dividend yield	—
Gross margin	26.1%
Operating margin	12.2%
Net margin	7.7%
Revenue growth (YoY)	-4.9%
Revenue growth (3-yr annual)	-1.0%
EPS growth (YoY)	+36.2%
FCF/share growth (YoY)	+33.8%
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

MD earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $0.63). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.72	$0.65	+10.8%	$501.37M
Q2 2026	Aug 4, 2026	$0.63	$0.59	+6.8%	$487.78M
Q1 2026	May 5, 2026	$0.44	$0.38	+15.8%	$476.20M
Q4 2025	Feb 19, 2026	$0.50	$0.54	-7.4%	$493.77M

MD analyst price target

Median target $29.00 from 6 analysts, ranging $28.00 – $31.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live MD data on Nama Insights →

MD FAQ

Is MD a buy?: Nama's AI scorecard currently rates Pediatrix Medical Group Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is MD's P/E ratio?: Pediatrix Medical Group trades at a trailing price-to-earnings ratio of 13.7.
When does MD report earnings?: Pediatrix Medical Group's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.63.
What is the MD price target?: The median analyst price target from 6 analysts is $29.00, with a range of $28.00 – $31.00.
Is MD Shariah compliant?: Nama's AAOIFI-style screen reads Pediatrix Medical Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.